financetom
Business
financetom
/
Business
/
RBC on Canadian Rail Update
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RBC on Canadian Rail Update
Dec 10, 2024 8:42 AM

11:29 AM EST, 12/10/2024 (MT Newswires) -- RBC, in its Dec. 9 rail update, reports that CPKC put up the best growth this week on the back of continued strength in Grain. Volumes at CN Rail were down driven by lower petroleum & chemicals RTMs.

QTD CP is outperforming CN mainly due to higher Grain shipments at CP and reflecting weakness across most segments at CN, in addition to being less exposed to Canadian port issues.

CP last week placed a follow-on order for the initial supply of 98 fuel cell engines. This follows the completion last month of construction of hydrogen production and refueling facilities in Calgary and Edmonton (both of which are now operational). CP is also retrofitting several diesel locomotives with hydrogen fuel cells so they can operate directly without generating emissions. These new fuel cell engines and fueling facilities are an important step forward in utilizing hydrogen as a fuel source, notes RBC.

"We continue to view this as a positive development from both an ESG and profitability standpoint-and highlight that CP currently has three hydrogen locomotives in operation." Diesel-powered locomotives is the rail industry's most significant source of greenhouse gas (GHG) emissions. Fuel comprised 14% of freight revenue at CPKC in 2023, RBC added.

Price: 151.50, Change: +0.64, Percent Change: +0.42

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Theravance Biopharma to Restructure After Ampreloxetine Trial Fails to Meet Endpoint
Theravance Biopharma to Restructure After Ampreloxetine Trial Fails to Meet Endpoint
Mar 11, 2026
09:35 AM EST, 03/03/2026 (MT Newswires) -- Theravance Biopharma ( TBPH ) shares fell by more than 26% in early trading Tuesday after the company said its blood pressure drug ampreloxetine failed to meet its primary endpoint in a phase 3 trial. As a result, the company said it will wind down its ampreloxetine program, accelerate a review to evaluate...
AM Best Comments on Credit Ratings of Zurich Insurance Group Ltd and Its Main Rated Subsidiaries
AM Best Comments on Credit Ratings of Zurich Insurance Group Ltd and Its Main Rated Subsidiaries
Mar 11, 2026
LONDON--(BUSINESS WIRE)-- AM Best has commented that the Financial Strength Ratings of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “aa” (Superior) of the main rated insurance subsidiaries of Zurich Insurance Group Ltd (Zurich) (Switzerland), as well as the Long-Term ICR of “a+” (Excellent) of Zurich (a non-operating holding company), remain unchanged following the announcement on March...
Affirm, Stripe Expand Partnership to Support Shared Payment Tokens for Agentic Commerce
Affirm, Stripe Expand Partnership to Support Shared Payment Tokens for Agentic Commerce
Mar 11, 2026
09:36 AM EST, 03/03/2026 (MT Newswires) -- Affirm (AFRM) said Tuesday that it is expanding its partnership with Stripe to support Shared Payment Tokens that allow artificial intelligence agents to initiate purchases using a shopper's permission and preferred payment method, without exposing sensitive credentials. Financial details of the expanded collaboration were not disclosed. The collaboration aims to bring Affirm's pay-over-time...
Theravance plans strategic review, including possible sale, after drug trial failure
Theravance plans strategic review, including possible sale, after drug trial failure
Mar 11, 2026
March 3 (Reuters) - Theravance Biopharma ( TBPH ) said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder failed to meet the main goal in a late-stage study. The drug ampreloxetine was being tested in people with multiple system atrophy, a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved